<DOC>
	<DOC>NCT02245516</DOC>
	<brief_summary>The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.</brief_summary>
	<brief_title>Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema</brief_title>
	<detailed_description>This is a multicenter, randomized, single-masked study evaluating the safety and effect of topical ocular administration of either KPI-121 0.25% ophthalmic suspension or KPI-121 1.0% ophthalmic suspension in subjects with intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Have documented presence of intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema at Screening Treatment with topical, intravitreal injection, posterior subTenon's, or periocular corticosteroids within 120 days prior to Visit 1 and for the duration of the study History of uncontrolled glaucoma, IOP over 21 mmHg at Visit 1, or are being treated for glaucoma in the study eye Any significant ocular disease that could compromise vision in the study eye (including ongoing ocular infection, wet agerelated macular degeneration, myopic degeneration with active subfoveal choroidal neovascularization) Known hypersensitivity or contraindication to the investigational product(s) or their components Diagnosis of severe/serious ocular condition that in the judgment of the Investigator could confound study assessments or limit compliance; or severe/serious systemic disease or uncontrolled medical condition that in the judgment of the Investigator could confound study assessments or limit compliance Exposed to an investigational drug within 30 days prior to Visit 1 and for the duration of the study In the opinion of the Investigator or study coordinator, an unwillingness or inability to comply with the study protocol or inability to successfully instill eye drops</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Intraretinal Fluid</keyword>
	<keyword>Subretinal Fluid</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>